

Atty. Dkt. No. 069748-0146

Amendments to the Claims:

The following listing incorporates the Examiner's amendments accompanying a Notice of Allowance dated June 16, 2006, and will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Previously presented) An isolated or purified OMP106 polypeptide, to between 70% and 99% pure by weight, which is an outer membrane polypeptide of *Moraxella catarrhalis*, and which has a molecular weight of about 180 kD to about 230 kD as determined in SDS polyacrylamide gel electrophoresis using rabbit skeletal muscle myosin and *E. coli* B-galactosidase as the 200 kD and 116.25 kD molecular weight standards, respectively, and which comprises the amino acid sequence of SEQ ID NO: 9.

2. (Original) The OMP106 polypeptide of claim 1, which has a molecular weight of about 190 kD.

3-4. (Canceled)

5. (Currently amended) The OMP106 polypeptide of claim [[3]] 1, wherein the *Moraxella catarrhalis* strain is a hemagglutinating cultivar.

6. (Original) The OMP106 polypeptide of claim 1, which reacts with silver stain.

7. (Previously presented) The OMP106 polypeptide of claim 1, which specifically binds an antibody that specifically binds a polypeptide having amino acid sequence of SEQ ID NO: 12.

8. (Previously presented) The OMP106 polypeptide of claim 1, which specifically binds an antibody that specifically binds a polypeptide having amino acid sequence of SEQ ID NO: 11.

9-51. (Canceled)

Atty. Dkt. No. 069748-0146

52. (Previously presented) The OMP106 polypeptide of claim 1, which specifically binds an antibody that specifically binds a polypeptide having amino acid sequence of SEQ ID NO: 9.

53. (Previously presented) An antigenic composition comprising the OMP106 polypeptide of claim 52, further comprising an adjuvant.

54. (Previously presented) An antigenic composition comprising the OMP106 polypeptide of claim 52 and a pharmaceutically acceptable carrier.

55-56. (Canceled)

57. (Previously presented) An isolated or purified OMP106 polypeptide, between 70% and 99% pure by weight, which consists of an amino acid sequence selected from the group consisting of:

A. SEQ ID NO: 1;

B. SEQ ID NO: 9;

C. SEQ ID NO: 11; and

D. SEQ ID No. 2, wherein said polypeptide specifically binds an antibody that specifically binds a polypeptide having amino acid sequence of SEQ ID NO: 9.

58. (Previously presented) An isolated OMP-106 polypeptide fragment consisting of 6 or more continuous amino acid residues of the sequence shown in SEQ ID NO: 1 wherein said fragment is recognized by an antibody that specifically binds a polypeptide comprising SEQ ID NO: 1.

59. (Previously presented) An isolated chimeric OMP106 polypeptide producible by a transformed host containing an expression vector consists of a nucleic acid sequence which encodes an amino acid sequence selected from the group consisting of:

A. SEQ ID NO: 1;

Atty. Dkt. No. 069748-0146

- B. SEQ ID NO: 9;
- C. SEQ ID NO: 11; and
- D. SEQ ID No. 2, wherein said polypeptide specifically binds an antibody that

specifically binds a polypeptide having amino acid sequence of SEQ ID NO: 9.

60. (Currently amended) An isolated antigenic composition comprising the OMP106 polypeptide of any one of claims 1, 2, ~~3, 4~~, 5, 6, 7, 8, 52, 53, 54, 57, 58 or 59.

61. (Previously presented) The isolated antigenic composition of claim 60 further comprising a pharmaceutically acceptable carrier.

62. (Currently amended) An isolated immunogenic composition comprising the OMP106 polypeptide of any one of claims 1, 2, ~~3, 4~~, 5, 6, 7, 8, 52, 53, 54, 57, 58 or 59.

63. (Previously presented) The immunogenic composition of claim 62 further comprising a pharmaceutically acceptable carrier.

64. (Canceled)

65. (Previously presented) An isolated or purified OMP106 polypeptide consisting of the amino acid sequence of SEQ ID NO: 1.

66. (Previously presented) An isolated or purified OMP106 polypeptide comprising the amino acid sequence of SEQ ID NO: 9.